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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the American Eng-
lish language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating 
centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical 
validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/
ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity 
(convergent and discriminant validity). A total of 315 JIA patients (5.1% systemic, 31.1% oligoarticular, 34% RF negative 
polyarthritis, 29.8% other categories) and 98 healthy children, were enrolled in three centres. The JAMAR components 
discriminated well healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. 
In conclusion, the American English version of the JAMAR is a valid tool for the assessment of children with JIA and is 
suitable for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally 
adapt and validate the American English parent, child/
adult version of the Juvenile Arthritis Multidimensional 
Assessment Report (JAMAR) [1] in patients with juvenile 
idiopathic arthritis (JIA). The JAMAR assesses the most 
relevant parent/patient-reported outcomes in JIA, includ-
ing overall well-being, functional status, health-related 
quality of life (HRQoL), pain, morning stiffness, disease 
activity/status/course, articular and extra-articular involve-
ment, drug-related side effects/compliance and satisfaction 
with illness outcome.
This project was part of a larger multinational study 
conducted by the Paediatric Rheumatology International 
Trials Organisation (PRINTO) [2] aimed to evaluate the 
Epidemiology, Outcome and Treatment of Childhood 
Arthritis (EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adap-
tation and validation of the parent and patient versions of 
the JAMAR in the American English language.
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Materials and methods
The methodology employed has been described in detail 
in the introductory paper of the supplement [4]. In brief, 
it was a cross-sectional study of JIA children, classified 
according to the ILAR criteria [5, 6] and enrolled from 
March 2012 to December 2013. Children were recruited 
after Ethics Committee approval and consent from at least 
one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10];
 2. rating of the intensity of the patient’s pain on a 21-num-
bered circle Visual Analogue Scale (VAS) [11];
 3. assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. assessment of morning stiffness (present/absent);
 5. assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. rating of the level of disease activity on a 21-circle 
VAS;
 7. rating of disease status at the time of the visit (categori-
cal scale);
 8. rating of disease course from previous visit (categori-
cal scale);
 9. checklist of the medications the patient is taking (list 
of choices);
 10. checklist of side effects of medications;
 11. report of difficulties with medication administration 
(list of items);
 12. report of school/university/work problems caused by 
the disease (list of items);
 13. assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. a question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. For the 
American English version of JAMAR, cross-cultural adap-
tation of the British English version was performed. Reading 
comprehension and understanding of the translated question-
naires were tested in a probe sample of 10 JIA parents and 
10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy chil-
dren and their parents.
The statistical validation phase explored the descrip-
tive statistics and the psychometric issues [16]. In par-
ticular, we evaluated the following validity components: 
the first Likert assumption [mean and standard deviation 
(SD) equivalence]; the second Likert assumption or equal 
items-scale correlations (Pearson r: all items within a scale 
should contribute equally to the total score); third Lik-
ert assumption (item internal consistency or linearity for 
which each item of a scale should be linearly related to the 
total score that is 90% of the items should have Pearson 
r ≥ 0.4); floor/ceiling effects (frequency of items at lower 
and higher extremes of the scales, respectively); internal 
consistency, measured by the Cronbach’s alpha, interscale 
correlation (the correlation between two scales should be 
lower than their reliability coefficients, as measured by 
Cronbach’s alpha); test–retest reliability or intra-class 
correlation coefficient (reproducibility of the JAMAR 
repeated after 1 or 2 weeks); and construct validity in its 
two components: the convergent or external validity which 
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examines the correlation of the JAMAR sub-scales with 
the 6 JIA core set of variables, with the addition of the par-
ent assessment of disease activity and pain by the Spear-
man’s correlation coefficients (r) [17] and the discriminant 
validity, which assesses whether the JAMAR discriminates 
between the different JIA categories and healthy children 
[18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete American English parent and patient ver-
sions of the JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The American English JAMAR was fully cross-culturally 
adapted from the British English version with no forward 
and backward translation.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the 10 parents tested 
(median = 100%; range 90–100%). All the 120 lines of the 
patient version of the JAMAR were understood by at least 
80% of the children (median = 100%; range 90–100%). Both 
versions of the JAMAR were unmodified after the probe 
technique.
Demographic and clinical characteristics 
of the subjects
A total of 315 JIA patients and 98 healthy children (total 
of 413 subjects), were enrolled at three paediatric rheu-
matology centres.
In the 315 JIA subjects, the JIA categories were 5.1% 
with systemic arthritis, 31.1% with oligoarthritis, 34% 
with RF negative polyarthritis, 5.1% with RF positive 
polyarthritis, 8.9% with psoriatic arthritis, 10.8% with 
enthesitis related arthritis and 5.1% with undifferentiated 
arthritis (Table 1).
A total of 369/413 (89.3%) subjects had the parent 
version of the JAMAR completed by a parent (277 from 
parents of JIA patients and 92 from parents of healthy 
children). The JAMAR was completed by 307/369 (83.2%) 
mothers and 62/369 (16.8%) fathers. The child version of 
the JAMAR was completed by 240/413 (58.1%) children 
age 7.2 or older.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all JAMAR items, the median number of missing 
responses were 0.0% (0.0–0.4%).
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items except for item 8, whereas a reduced number 
of response choices were used for PF items 11 and 12.
The mean and SD of the items within a scale were roughly 
equivalent for the PF and for the HRQoL items, except for 
HRQoL item 5 (data not shown). The median number of 
items marked as not applicable was 1% (0.0–5.0%) for the 
PF and 1.5% (0.0–8.0%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 85.9% (74.7–94.6%) for the 
PF items, 68.8% (31.8–88.4%) for the HRQoL PhH items, 
and 67.1% (64.3–83.8%) for the HRQoL PsH items. The 
median ceiling effect was 0.4% (0.0–1.4%) for the PF 
items, 2.2% (0.4–7.9%) for the HRQoL PhH items, and 
1.1% (0.0–1.1%) for the HRQoL PsH items. The median 
floor effect was 33.9% for the pain VAS, 35.7% for the 
disease activity VAS and 41.9% for the well-being VAS. 
The median ceiling effect was 0.0% for the pain VAS, 
4.0% for the disease activity VAS and 0.7% for the well-
being VAS.
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Table 1  Descriptive statistics (medians, 1st 3rd quartiles or absolute frequencies and %) for the 315 JIA patients
Data related to the JAMAR refers to the 277 JIA patients and to the 92 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD Medical Doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic Oligoarthritis RF− poly-
arthritis
RF+ poly-
arthritis
Psoriatic 
arthritis
Enthesitis 
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 16 N = 98 N = 107 N = 16 N = 28 N = 34 N = 16 N = 315 N = 98
Female 7 (43.8%) 79 (80.6%) 94 (87.9%) 14 (87.5%) 18 (64.3%) 15 (44.1%) 10 (62.5%) 237 (75.2%)** 49 (50%)#
Age at visit 10.8 
(7.9–12.4)
11.7 (8–15.6) 13.5 (10.9–
16.8)
15.6 (13.3–
16.8)
14.2 
(11–16.5)
14.5 (10.4–
15.9)
15.1 (13.7–
16.8)
13.5 (10.1–
16.1)*
12 (8.1–
15.4)*
Age at onset 5.5 (2.7–10.7) 4 (2.4–8.7) 7.4 (3.3–11) 11.5 (9–13.2) 9.2 (6–12.3) 10.4 
(6.8–12.5)
9.5 (8.3–12.9) 7.8 (3.3–11.1)*
Disease duration 3.4 (1.6–6.1) 4.9 (1.6–7.9) 4.2 (2–9.3) 2.4 (1.7–6.5) 3.9 (2.2–6.2) 3 (1.7–6) 4.3 (1.2–6) 4.1 (1.8–7.9)
ESR 11 (5–18) 6 (4–12) 7 (5–13) 7 (6–20) 6.5 (3–10.5) 6.5 (2–14) 9.5 (6–11) 7 (4–13)
MD VAS 0 (0–0) 0 (0–1) 0 (0–2) 1 (0–2) 0 (0–2) 1 (0–3) 0.5 (0–3) 0 (0–2)*
No. swollen joints 0 (0–0) 0 (0–0) 0 (0–1) 0 (0–2) 0 (0–0) 0 (0–0) 0 (0–1) 0 (0–0)*
No. joints with 
pain
0 (0–0) 0 (0–0) 0 (0–1) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–1) 0 (0–0)
No. joints with 
LOM
0 (0–0) 0 (0–0) 0 (0–2) 0 (0–2) 0 (0–2) 0 (0–3) 1 (0–1.5) 0 (0–1)**
No. active joints 0 (0–0) 0 (0–0) 0 (0–1) 0 (0–2) 0 (0–0) 0 (0–0) 0 (0–1.5) 0 (0–1)*
Active systemic 
features
2 (12.5%) 2 (2%) 1 (0.9%) 0 (0%) 1 (3.6%) 0 (0%) 0 (0%) 6 (1.9%)
ANA status 0 (0%) 2 (2%) 3 (2.8%) 0 (0%) 2 (7.1%) 0 (0%) 1 (6.3%) 8 (2.5%)
Uveitis 1 (6.3%) 21/97 (21.6%) 9/105 (8.6%) 0 (0%) 3 (10.7%) 1/33 (3%) 1 (6.3%) 36/311 
(11.6%)*
PF Total Score 1 (0–4) 0 (0–2) 1 (0–4) 0 (0–3) 1 (0–4) 2 (0–7) 0 (0–4) 1 (0–4) 0 (0–0)#
Pain VAS 0.5 (0–2) 1 (0–3.5) 1 (0–2.5) 0.3 (0–1.5) 1 (0–3) 3 (1–5) 0 (0–3.5) 1 (0–3)* 0 (0–0)#
Disease Activity 
VAS
0.5 (0–2.5) 0.5 (0–4) 1 (0–3) 0.8 (0–5) 1 (0–5.5) 3 (1–7) 1 (0–3) 1 (0–4)
Well-being VAS 0 (0–2) 0.5 (0–2.5) 0.5 (0–2) 0 (0–3) 1 (0–2.5) 2 (1–3.5) 1 (0–3.5) 0.5 (0–3)*
HRQoL PhH 0 (0–5) 1 (0–4) 1 (0–4) 1 (0–1) 2 (1–4) 3 (2–5) 0 (0–2) 1 (0–4)* 0 (0–0)#
HRQoL PsH 0 (0–2) 0 (0–3) 1 (0–3) 0.5 (0–2) 2 (0–3) 2 (1–4) 1 (0–3) 1 (0–3) 0 (0–0)#
HRQoL Total 
Score
0 (0–6) 2 (0–6) 3 (1–7) 2 (0–5) 3 (2–7) 6 (3–9) 2 (0–5) 3 (1–7)* 0 (0–1)#
Pain/swell. in > 1 
joint
4 (26.7%) 44 (50.6%) 50 (55.6%) 5 (35.7%) 13 (56.5%) 27 (81.8%) 7 (46.7%) 150 (54.2%)* 2 (2.2%)#
Morning stiff-
ness > 15 min
3 (20%) 20 (23%) 21 (23.3%) 3 (21.4%) 4 (17.4%) 22 (66.7%) 1 (6.7%) 74 (26.7%)* 0 (0%)#
Subjective remis-
sion
4 (26.7%) 50 (57.5%) 49 (54.4%) 6 (42.9%) 12 (52.2%) 26 (78.8%) 9 (60%) 156 (56.3%)*
In treatment 13 (86.7%) 59 (67.8%) 80 (88.9%) 13 (92.9%) 20 (87%) 27 (81.8%) 10 (66.7%) 222 (80.1%)
Reporting side 
effects
2/13 (15.4%) 19/59 (32.2%) 24/80 (30%) 3/13 (23.1%) 9/20 (45%) 8/27 (29.6%) 1/10 (10%) 66/222 (29.7%)
Taking medication 
regularly
12/13 (92.3%) 57/59 (96.6%) 67/80 (83.8%) 12/13 (92.3%) 18/20 (90%) 26/27 (96.3%) 7/9 (77.8%) 199/221 (90%)
With problems 
attending school
1/8 (12.5%) 7/59 (11.9%) 10/63 (15.9%) 1/13 (7.7%) 3/17 (17.6%) 6/20 (30%) 1/14 (7.1%) 29/194 (14.9%) 0 (0%)**
Satisfied with dis-
ease outcome
13 (86.7%) 70 (80.5%) 71 (78.9%) 11 (78.6%) 18 (78.3%) 21 (63.6%) 11 (73.3%) 215 (77.6%)
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Equal items‑scale correlations (second Likert 
assumption)
Pearson items-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 87% of the PF 
items, with the exception of PF items 11 and 15, and for 80% 
of the HRQoL items, with the exception of items 1 and 8.
Items internal consistency (third Likert assumption)
Pearson items-scale correlations were ≥ 0.4 for 87% of items 
of the PF (except for PF items 11 and 15) and 100% of items 
of the HRQoL.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 277/369 Child N = 233/240
Missing values (1st–3rd quartiles) 0.0 (0.0–0.4) 0.0 (0.0–0.4)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 85.9% 88.0%
 HRQoL PhH 68.8% 71.2%
 HRQoL PsH 67.1% 69.5%
 Pain VAS 33.9% 33.1%
 Disease activity VAS 35.7% 40.3%
 Well-being VAS 41.9% 48.9%
Ceiling effect, median
 PF 0.4% 0.0%
 HRQoL PhH 2.2% 3.0%
 HRQoL PsH 1.1% 0.4%
 Pain VAS 0.0% 0.0%
 Disease activity VAS 4.0% 0.0%
 Well-being VAS 0.7% 0.4%
Items with equivalent item-scale correlation 87% for PF, 80% for HRQoL 80% for PF, 87% for HRQoL
Items with items-scale correlation ≥ 0.4 87% for PF, 100% for HRQoL 80% for PF, 90% for HRQoL
Cronbach’s alpha
 PF-LL 0.88 0.81
 PF-HW 0.87 0.81
 PF-US 0.72 0.71
 HRQoL-PhH 0.86 0.87
 HRQoL-PsH 0.77 0.73
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.92 0.47
 HRQoL-PhH 0.92 0.71
 HRQoL-PsH 0.83 0.11
Spearman’s correlation with JIA core-set variables, median
 PF 0.4 0.3
 HRQoL PhH 0.3 0.3
 HRQoL PsH 0.2 0.1
 Pain VAS 0.2 0.3
 Disease activity VAS 0.2 0.2
 Well-being VAS 0.3 0.3
S40 Rheumatology International (2018) 38 (Suppl 1):S35–S42
1 3
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.88 for PF-LL, 0.87 for PF-HW, 0.72 
for PF-US. Cronbach’s alpha was 0.86 for HRQoL-PhH and 
0.77 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 7 JIA patients, by re-administer-
ing both versions (parent and child) of the JAMAR after a 
median of 3 days (1–4 days). The intraclass correlation coef-
ficients (ICC) for the PF total score showed an almost perfect 
reproducibility (ICC = 0.92). The ICC for the HRQoL PhH 
and for the HRQoL PsH showed an almost perfect reproduc-
ibility (ICC = 0.92 and ICC = 0.83, respectively).
Convergent validity
The Spearman’s correlation of the PF total score with the 
JIA core set of outcome variables ranged from − 0.01 to 
0.6 (median = 0.4). The PF total score best correlation 
was observed with the parent assessment of pain (r = 0.6, 
p < 0.001). The correlation of the PF total score with the 
ESR was not significant (p = 0.87). For the HRQoL, the 
median correlation of the PhH with the JIA core set of 
outcome variables ranged from 0.1 to 0.7 (median = 0.3), 
whereas for the PsH ranged from 0.1 to 0.6 (median = 0.2). 
The PhH showed the best correlation with the parent’s 
assessment of pain (r = 0.7, p < 0.001) and the PsH with the 
parent global assessment of well-being (r = 0.6, p < 0.001). 
The median correlations between the pain VAS, the well-
being VAS, and the disease activity VAS and the physician-
centred and laboratory measures were 0.2 (− 0.01 to 0.4), 
0.2 (0.01–0.4), 0.3 (− 0.02 to 0.4), respectively.
Discussion
In this study, the American English version of the JAMAR 
was cross-culturally adapted from the British English ver-
sion. According to the results of the validation analysis, the 
American English parent and patient versions of the JAMAR 
possess satisfactory psychometric properties. The disease-
specific components of the questionnaire discriminated well 
between patients with JIA and healthy controls. The HRQoL 
total score proved to discriminate between the different JIA 
subtypes with children with enthesitis related arthritis hav-
ing a lower HRQoL.
Psychometric performances were good for all domains of 
the JAMAR with few exceptions: 2 PF items (stretch arms 
and bite a sandwich or an apple) showed a lower items inter-
nal consistency. However, the overall internal consistency 
was excellent for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from weak to moderate.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the American English version of the 
JAMAR was found to have satisfactory psychometric prop-
erties and it is, thus, a reliable and valid tool for the multidi-
mensional assessment of children with JIA.
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